CTN-0132: Ketamine for Methamphetamine Use Disorder (KMD)

November 9, 2021 /

Madhukar Trivedi, MD
Lead Investigator
University of Texas Southwestern Medical Center
madhukar.trivedi@utsouthwestern.edu

This study aims to 1) determine the feasibility, initial signal, and safety with 6 weeks of IV ketamine versus midazolam in individuals with MUD and 2) evaluate the efficacy and safety of ketamine compared to midazolam during the additional 6 weeks of the observational follow-up period.

    Node Involvement

    Lead Node(s):

  • Big South/West Node

    • All Participating Nodes:

  • Big South/West Node